About US
Contact us
-
Study shows experimental T-cell therapy puts cancer patients in remissionA study conducted by researchers at the Fred Hutchinson Cancer Research Centre has showed that the experimental, living T-cell therapy has put patients with cancer in remission. Patients with acute l2016/2/23
-
AstraZeneca bags EU approval for gout drug Zurampic as it eyes $500M in salesAstraZeneca ($AZN) snagged EU approval for its gout drug Zurampic, a few months after the med got an FDA green light. The regulatory blessing helps the U.K. drugmaker as it looks to new meds to fill t2016/2/22
-
Pfizer whistleblowers set to collect $59M in Medicaid fraud suitHow much does it pay to sue Big Pharma? In the case of one serial whistleblower, $59 million. Louisiana doctor William LaCorte is set to collect a boatload of cash after filing a whistleblower suit ag2016/2/22
-
WHO recommends control measures to tackle Zika virusThe World Health Organisation (WHO) has announced that the countries battling the Zika virus must implement new tools to prevent it from spreading. The virus is mainly linked to severe birth defects2016/2/19
-
Pfizer's subsidiary Wyeth to pay $784.6m to settle Medicaid rebates issuesPfizer subsidiary Wyeth has agreed to pay $784.6m to settle allegations related to the calculation of Medicaid rebates for its gastric drug Protonix (pantoprazole sodium) between 2001 and 2006. Medic2016/2/19
-
US FDA grants breakthrough status for Roche's ocrelizumab to treat PPMSThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche's investigational medicine, ocrelizumab (OCREVUSTM), for the treatment of primary progressive multiple2016/2/18
-
US FDA refuses to approve Merck's Zetia and Vytorin medicinesThe US Food and Drug Administration (FDA) has refused to approve Zetia and Vytorin, Merck's medicines that are used to reduce the risk of cardiovascular events in patients with coronary heart disease.2016/2/17
-
Sandoz buys rights to Pfizer’s infliximab biosimilar in EEANovartis' generic pharmaceuticals division Sandoz has acquired rights of Pfizer's PF-06438179, a biosimilar of Merck's Remicade (infliximab), in the European Economic Area (EEA), to treat a range of a2016/2/17
-
AstraZeneca, MedImmune, Lilly join U-M to discover new CKD treatmentsAstraZeneca and its global biologics research and development arm MedImmune have entered into collaboration with the University of Michigan and Eli Lilly to discover new therapeutic targets to treat c2016/2/16
-
FDA grants orphan status for ONL Therapeutics' ONL1204 to treat retinal detachmentThe US Food and Drug Administration (FDA) has granted orphan drug designation for ONL Therapeutics' first-in-class small molecule peptide, ONL1204, for the treatment of retinal detachment. ONL1204 is2016/2/16